Questran Lite

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Questran Lite

What is Questran Lite? (Overview)

Property Description
Active ingredient Colestyramine (Cholestyramine resin)
Form Powder for Oral Suspension, in sachets
Pharmacological class Bile Acid Sequestrant
Common Use Reduction of elevated cholesterol levels
Origin Synthetic (Styrene-divinylbenzene copolymer)

Questran Lite is a prescription-only pharmaceutical product whose active substance is the synthetic polymer known as Colestyramine or Cholestyramine resin. This brand is specifically marketed as the sugar-free formulation of the drug, distinguishing it from original preparations by utilizing aspartame as the sweetening agent. It is classified as a Bile Acid Sequestrant, belonging to the larger group of Antilipemic Agents designed to affect lipid metabolism. It is administered orally as a fine powder for suspension and is chemically designed to remain non-absorbed, acting exclusively within the intestinal tract.


What Type of Medicine is Questran Lite?

Colestyramine resin is chemically defined as a strong anion exchange resin, a type of synthetic material used to bind negatively charged molecules. The drug is clinically recognized for its effectiveness in managing certain lipid disorders and has a long-standing use as an adjunctive therapy to dietary changes for high cholesterol. The patient-friendly conclusion is that this medicine provides a long-established, safe option to help manage high cholesterol, particularly when combined with diet modification. Being a powdered form, it offers a specific mode of delivery that requires mixing with a non-carbonated liquid, differentiating it from tablet or capsule forms of other cholesterol-lowering agents.


General Principle: How Cholestyramine Affects the Body

Colestyramine's fundamental action is to bind firmly to bile acids in the small intestine, forming an insoluble complex that is then excreted in the feces. This removal of bile acids interrupts their normal enterohepatic recirculation. In response, the liver converts existing cholesterol into new bile acids to replenish the lost pool, resulting in the drug's essential hypolipidemic or cholesterol-lowering effect. These non-digestible resins bind to bile acids, leading to their excretion, which forms the established basis for their therapeutic use. This means the medicine works locally in the gut to reduce the body's cholesterol levels by forcing the liver to consume it for bile acid production.

Regulatory References

  1. NIH Cholestyramine Resin (StatPearls)

What side effects are possible with Questran Lite?

Possible Side Effects and Safety Information

The officially documented adverse reactions for Questran Lite, which contains the active ingredient cholestyramine resin, are primarily concentrated in the gastrointestinal system and the metabolism and nutritional system.

According to regulatory classification, constipation is the most frequent adverse reaction, listed as very common. Other common or uncommon gastrointestinal effects include abdominal discomfort, pain, flatulence, nausea, and vomiting. These are consistent with the medicine's non-absorbed action within the digestive tract.

Safety notes specify that long-term or chronic use is associated with distinct consequences. Due to the drug's binding action, there is a risk of deficiencies in fat-soluble vitamins (A, D, E, and K), which can lead to documented issues such as osteoporosis and an increased risk of bleeding tendencies (hypoprothrombinemia). Prolonged exposure may also lead to hyperchloraemic acidosis.

Rare, but serious, adverse reactions officially documented in regulatory sources include intestinal obstruction and pancreatitis.

Specific safety considerations are noted for certain populations. The official label indicates caution for older adults due to an increased potential for severe constipation, and notes for pediatric patients regarding a higher relative risk of hyperchloraemic acidosis. The medicine is formally contraindicated in individuals with complete biliary obstruction or known hypersensitivity to bile acid sequestrants. This official safety profile structures the understanding of risks around predictable digestive complaints and the need for long-term observation concerning metabolic changes.

Overdose and Emergency Response

Overdose and when to seek help

Questran Lite (Colestyramine) is a non-systemic agent, and its official regulatory overdose profile is defined by physical consequences within the gastrointestinal tract. The chief potential harm documented in regulatory prescribing information following an overdosage is obstruction of the gastrointestinal tract. Documented clinical manifestations of overdose are primarily local, including reports of severe stomach or abdominal pain and constipation.

When to Seek Immediate Medical Help

Regulatory authorities mandate that users seek emergency medical attention or contact a poison control center immediately if an overdose is suspected. This immediate action is required even if initial discomfort is minimal or absent, due to the potential for serious complications. Immediate medical help must also be sought if any serious symptoms, such as passing out or trouble breathing, occur.

Treatment and Special Considerations

No specific antidote is known for Colestyramine overdose. Treatment is strictly symptomatic and supportive, with management for any resulting obstruction determined by its specific location and degree. Of critical regulatory concern are pediatric patients, who have been associated with rare reports of severe outcomes, including fatal intestinal obstruction, as noted in official prescribing information. The risk of hyperchloremic acidosis with prolonged, high-dose administration is also noted in official labeling for smaller individuals or those with renal impairment.

Therapeutic Uses of Questran Lite

What Questran Lite Treats: Main Uses and Benefits

Questran Lite, which contains the active ingredient cholestyramine, is commonly used across conditions presenting with episodic or fluctuating manifestations. It is applied across therapeutic domains where additional symptomatic support is needed. Its therapeutic use is considered relevant for two principal indications: elevated serum cholesterol (hyperlipidemia), and pruritus (itching) associated with partial biliary obstruction.

The medicine is applied in scenarios where additional management of discomfort is required. The primary use is to help with elevated cholesterol, specifically LDL cholesterol, an action that contributes to easing the symptoms linked to organ-specific functional stress. It may also assist with the management of chronic diarrhea resulting from bile acid malabsorption.

The patient benefit may be part of symptomatic management to help improve day-to-day comfort during symptomatic periods, particularly with itching.

“This supportive assistance helps patients cope more steadily with symptom fluctuations.”

Supportive symptom management is appropriate for pruritus associated with partial biliary obstruction, providing assistance when symptoms interfere with daily functioning.


Quick Fact: Symptomatic support for Pruritus


Regulatory References

  1. NIH LiverTox entry on Cholestyramine

Eligibility and Restrictions for Use

The eligibility to use Questran Lite (colestyramine) is strictly defined by official regulatory labeling, outlining specific populations who must not use the medicine and those who require conditional use.

Eligibility Classification Patient Groups
Contraindicated Patients with complete biliary obstruction (no bile secretion into the intestine) or known hypersensitivity to colestyramine [1.1, 2.5]. Use of Questran Lite is also prohibited for patients with Phenylketonuria (PKU) because the Lite formulation contains aspartame [1.1].
Requires Caution Older adults may be more susceptible to gastrointestinal side effects [1.2]. Patients with renal impairment or volume depletion are at risk of developing hyperchloremic acidosis [2.3]. Individuals with pre-existing constipation require careful monitoring to prevent impaction [2.2].

Age and Physiological States

  • Adults are the primary population with established safety profiles [1.4].
  • Children under 6 years are not recommended to use the medicine due to insufficient data to establish an optimal dosage schedule or long-term safety [1.4].
  • Pregnancy and Lactation: Use during pregnancy is generally considered safe but requires careful assessment as the drug may interfere with the maternal absorption of fat-soluble vitamins (A, D, E, K). Caution is advised when administering to nursing mothers for the same reason [1.6, 2.4].
  • Comorbidities: Secondary causes of hypercholesterolemia, such as hypothyroidism or diabetes, should be managed or excluded before initiating this therapy [1.5].

What should I know about interactions with other medicines?

Questran Lite (colestyramine resin) interacts with numerous other products primarily by binding them in the digestive tract, which results in reduced systemic exposure of the co-administered drug. The official regulatory profile is dominated by constraints related to this binding action.

Documented Interaction Constraints

Classification Interacting Medicines and Substances
Exposure Reduction Thyroid hormones (e.g., Levothyroxine), Digitalis glycosides (e.g., Digoxin), Warfarin, Thiazide diuretics, Estrogens, and several antibiotics and NSAIDs
Pharmacodynamic Effect HMG-CoA reductase inhibitors (Statins) and Nicotinic Acid (results in enhanced lipid-lowering effects)
Nutritional Interference Fat-Soluble Vitamins (A, D, E, K) and Folic Acid (absorption is impaired)

All other oral medicines must be administered at least one hour before or 4 to 6 hours after Questran Lite to minimize interference with their absorption, a timing requirement stated explicitly in regulatory labeling. The product is also restricted from use in patients diagnosed with complete biliary obstruction.

Population-specific notes include an increased risk for developing hyperchloraemic acidosis in smaller patients and those with renal impairment, which requires medical monitoring. The official interaction profile is classified as physicochemical interference, which creates specific challenges in drug scheduling.

Mechanism of Action

How Questran Lite Works: Mechanism of Action

Bile Acid Sequestration and Enterohepatic Interruption

The drug, a sequestrant resin, initiates its action by physical binding to bile acids within the small intestine. This interaction forms a large, non-absorbable complex that is confined to the gastrointestinal lumen. This process prevents the normal reabsorption of bile acids via the enterohepatic circulation (the recycling pathway between the gut and the liver), forcing their subsequent excretion from the body.

Upregulation of Hepatic Cholesterol Metabolism

The ensuing loss of bile acids triggers a homeostatic response in the liver, which must synthesize replacements. This physiological step involves the upregulation of Low-Density Lipoprotein (LDL) receptors on the surface of liver cells. These receptors actively extract circulating LDL cholesterol from the bloodstream. The extracted LDL cholesterol is then used in de novo bile acid synthesis, resulting in its clearance from the plasma.

Resulting Physiological Effect

The combined mechanistic cascade, involving peripheral sequestration and central hepatic compensation, leads to an alteration of the body’s lipid transport profile. This increased extraction of LDL-C from the plasma is the systemic physiological consequence of the drug's mechanism of action on lipid homeostasis.

Dosage and Administration Information

How to Use Questran Lite: Official Administration Guidelines

Questran Lite (cholestyramine resin) is administered according to official prescribing information that focuses on precise dosing, preparation, and timing relative to other medicines. The entire administration protocol is designed for oral intake only, consistent with its form as a Powder for Oral Suspension.


Preparation and Timing Requirements

The powder must never be taken in its dry form to avoid the risk of mucosal irritation or potential obstruction. A single dose of the powder must be fully suspended by mixing with at least 60 mL (2 oz) of water or other non-carbonated liquid until a uniform consistency is achieved. Suitable vehicles include fruit juice or high-moisture foods such as applesauce.

To ensure optimal absorption of co-administered oral medications, the administration of Questran Lite must be separated from other oral drugs. Other medications should be taken at least one hour before or four to six hours after a dose of cholestyramine resin.


Standard Dosing Regimens

Doses are expressed in grams of the anhydrous resin, with each sachet typically containing 4 g.

Administration Parameter Official Guideline
Starting Adult Dose 4 g once or twice daily.
Maintenance Range 8 g to 16 g daily.
Maximum Daily Dose 24 g (equivalent to six sachets or scoopfuls).
Frequency Doses are typically divided and administered two to four times per day, often suggested at mealtimes.

Dosage adjustments, if required, are implemented gradually over intervals of not less than four weeks. While no specific dose change is noted for older adults, official information indicates that the dosage has not been established for routine use in infants and younger children.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Questran Lite

Evidence for Use in Elevated LDL Cholesterol

Research on cholestyramine, the active ingredient in Questran Lite, was studied for its role in managing conditions related to elevated cholesterol, which are outcomes related to systemic or functional imbalance. The most comprehensive evidence for this use comes from large-scale, long-term Randomized Controlled Trials (RCTs). These studies research examined patterns related to lipid biomarker changes and the occurrence of major cardiovascular events in adult men with high cholesterol. Landmark trials data show patterns related to a lower rate of combined fatal and non-fatal heart events in those studied populations compared to control groups.

Evidence for Symptomatic Relief of Pruritus (Itching)

The medicine was evaluated in patients with severe itching (pruritus) related to partial blockage of bile flow. The evidence exploring this use is based on smaller-scale randomized controlled trials. These studies monitored patient-reported outcomes describing discomfort over short, defined time intervals. However, the certainty remains low for this use because the follow-up durations were limited, and the evidence quality varies across studies and systematic reviews.

Long-Term Research and Durability of Study Findings

Long-term research was studied for the elevated cholesterol indication, with follow-up periods extending up to seven years in some pivotal trials. However, the long-term effects are not fully established for the symptomatic relief indication, as those studies were typically short-term and focused on immediate changes.

Evidence in Specific Patient Groups

Research was evaluated in pediatric patients (children and adolescents) with very high cholesterol. For other specific groups, such as older adults and pregnant individuals, data for certain groups remain insufficient. Subgroup findings are uncertain when trying to apply the main evidence patterns to populations with different characteristics than those studied.

What is Still Uncertain About the Research Record

One key limitation is that the long-term cardiovascular findings results apply only to the populations studied in the primary trials—predominantly middle-aged men. Therefore, the long-term cardiovascular impact in women is not fully established through similarly rigorous trials. For the symptomatic use, comparative evidence is lacking for certain outcomes, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Questran Lite (FAQ)


Q: Does Questran Lite contain sugar or sweeteners?

Official product information describes Questran Lite as the sugar-free formulation of cholestyramine. It contains aspartame as a sweetener. The presence of aspartame means this formulation contains phenylalanine, which is an important note for individuals with phenylketonuria (PKU).


Q: Are there any specific foods that should be avoided while taking Questran Lite?

Regulatory documents do not provide a list of specific foods to avoid, but they do note the medicine's binding action may interfere with the absorption of fat-soluble vitamins (A, D, E, K) and folic acid. Regulatory documents describe the requirement to separate the administration time of this medicine from other oral drugs and supplements to minimize potential interference.


Q: Is it safe to take Questran Lite with common over-the-counter pain relievers?

Official product labeling indicates that cholestyramine resin has been studied to reduce the absorption of certain oral medications, including some NSAIDs (non-steroidal anti-inflammatory drugs) and acetaminophen. The official product timing requirement states that other oral drugs must be administered at least one hour before or four to six hours after Questran Lite.


Q: Can Questran Lite be used during pregnancy or while breastfeeding?

The medicine itself is generally considered non-absorbed by the body. However, official information notes that use during pregnancy or while nursing is subject to careful medical assessment because the medicine may interfere with the mother’s absorption of fat-soluble vitamins. This potential lack of proper vitamin absorption could potentially affect the nursing infant.


Q: What if I have trouble swallowing the mixed powder?

The powder must always be mixed with at least 60 mL of liquid before consumption. Official guidelines suggest using vehicles such as water, fruit juice, or high-moisture foods like applesauce to aid consumption. Official guidelines recommend rinsing the glass with extra liquid after administration to ensure the full dose amount is received.


Q: Is Questran Lite considered a permanent treatment?

The medicine is officially described as an adjunctive therapy—meaning it is used alongside, and in addition to, dietary changes. The label also contains specific warnings regarding the consequences of chronic use, such as the potential for vitamin deficiencies, which implies use over an extended period.


Q: Is it common to experience a change in bowel habits with Questran Lite?

Changes in the digestive system are common, as the medicine works directly in the gut. Regulatory documents list constipation as the most frequent adverse reaction. Other common gastrointestinal effects described include flatulence, abdominal discomfort, nausea, and vomiting.


Q: If I stop taking Questran Lite, will my condition immediately return?

Patient guidance based on official information indicates that if the treatment is stopped, blood cholesterol levels may increase again. Patient guidance mentions that continuation of a special diet may be necessary after cessation of the medicine to help manage the patient's condition.


Q: Are weight changes a possible side effect of Questran Lite?

Official regulatory documents list both weight loss and weight gain as possible adverse reactions associated with the use of the medicine, although the frequency of these particular side effects is not commonly reported or established.


Q: Does Questran Lite have a strong taste?

The pure powder is chemically described as having an odorless or slight amine odor. While the Lite formulation is sweetened with aspartame, some product reports have noted it can cause a sour taste or irritation of the tongue for some users.


Q: Can Questran Lite interfere with the effectiveness of birth control pills?

Official documents note that the medicine may interfere with the absorption of certain estrogens, such as ethinyl estradiol, which is an active ingredient in many oral contraceptives. The administration timing separation requirement, as defined in the official labeling, applies to minimize this potential interaction.


Q: Does using Questran Lite mean I no longer need to diet?

Questran Lite is officially indicated as an adjunctive therapy to diet for the reduction of elevated cholesterol. Treatment is intended to begin and continue alongside dietary changes specific to the condition being managed, and it does not replace the need for diet.


Q: How does Questran Lite compare to other bile acid sequestrants?

Questran Lite belongs to the therapeutic class known as Bile Acid Sequestrants. This class is comprised of multiple medicines that share the common mechanism of binding bile acids in the intestine. Regulatory documents classify it as one option within this broader class of cholesterol-lowering agents.


Q: Why is the full effect of Questran Lite sometimes not seen for several weeks?

Official clinical data suggests that the full therapeutic effect of the medicine may not be observed until approximately 21 days after treatment has begun. This time frame allows for the drug's mechanism to fully establish the changes in the body's lipid transport profile.


Q: Is the mechanism of action the same for all its approved uses?

Yes. For all approved uses, including cholesterol management and symptomatic relief of itching, the fundamental mechanism is the adsorption and binding of bile acids in the intestine. For symptomatic relief of itching, this binding reduces the level of bile acids in the body that contribute to the discomfort.


Q: Does Questran Lite cause or worsen constipation?

Constipation is listed in official documents as the most frequent adverse reaction. Regulatory precautions note that the medicine may also produce or worsen pre-existing constipation. The label highlights the need for caution and monitoring to minimize the risk of developing a serious condition like fecal impaction.

How should Questran Lite be stored and disposed of?

How to Store and Dispose of Questran Lite

Storage Requirements

Questran Lite powder must be stored at controlled room temperature, specifically between 20^circ to 25 C (68^circ to 77 F), with excursions permitted up to 30 C (86 F). The product must be protected from moisture and kept in a cool, dry place. It is officially mandated that, for product dispensed in a can, the plastic lid must be replaced after every use to maintain product quality.

Child Safety and Disposal

For safety, the medicine must always be stored in a location that is out of the reach of children.

Any unused or expired Questran Lite or associated waste material must be disposed of in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Questran Lite found in:

A-Z Index: